Tumor-derived immunoglobulin idiotype

Tumor-derived immunoglobulin idiotype is the unique structure formed by the variable regions of the immunoglobulin molecules expressed by individual malignant B cells. This idiotype, defined by somatic recombination and mutation events, acts as a tumor-specific marker because it is clonally unique to the tumor cells and not shared by normal cells. It can function as a true tumor-specific antigen, making it an attractive immunotherapy target in B-cell lymphoma and related malignancies. Therapeutic strategies include both passive antibody therapy and active vaccination against the idiotype to induce patient-specific anti-tumor immune responses[1][2][3][4][5]. The approach is highly personalized, as each tumor expresses a different idiotype; clinical responses have been documented, but challenges include tumor immune escape due to idiotype mutation and the need for individualized manufacturing for each patient. Emerging research also implicates tumor-derived immunoglobulin idiotypes in promoting tumor proliferation, metastasis, and immune evasion[5].

Other names

Tumor immunoglobulin idiotypeTumor Ig idiotypeTumor-specific idiotypeB-cell tumor idiotype

Induction of anti-tumor immune responses by targeting the unique idiotype of malignant B cells (active immunization); Direct antibody-mediated cytotoxicity (passive immunization with anti-idiotype antibodies); T cell activation against tumor idiotype antigens; Other